{"metadata": {"source": "erowid", "title": "Erowid Psilocybin & Psilocin Vault : Legal Status", "description": "Information on the legal status of Psilocybin & Psilocin.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/psilocybin/psilocybin_law.shtml", "drug": "Psilocybin", "cid": 10624, "substance": "psilocybin", "category": "CHEMICALS", "erowid_column": "Law", "char_count": 7199, "word_count": 1021, "doc_id": "doc_219", "num_chunks": 9, "chunk_id": "219::chunk_6", "document_index": 219, "latency_s": 1.2673293999978341, "prompt_toks": 2082, "completion_toks": 83, "relevance_score": 0.0002758679}, "content": "Drug: Psilocybin | cid: 10624\nSource: erowid | Source description: Information on the legal status of Psilocybin & Psilocin.\nErowid name: psilocybin\nCategory: CHEMICALS\nField: Law\n\n                    Text: \n                    Department personnel, shall use any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the use and possession of Entheogenic Plants by adults; [... and ...] RESOLVED That the Mayor and City Council hereby declare that it shall be the policy of the City of Oakland that the investigation and arrest of adult persons for planting, cultivating, purchasing, transporting, distributing, engaging in practices with, and/or possessing Entheogenic Plants or plant compounds on the Federal Schedule 1 list shall be amongst the lowest law enforcement priority for the City of Oakland; [...]\" (last updated June 4 2019)\n\n\n                    Context: \n                    This excerpt details Oakland's local policy prioritizing decriminalization and low enforcement regarding entheogenic plants, including psilocybin mushrooms, within the broader context of the webpage's focus on drug legality and law reform at state and international levels. It highlights Oakland's specific resolution on deprioritizing investigations and arrests related to Schedule 1 entheogenic plants, emphasizing its significance in current legal and activism discussions.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Amphetamines Vault : Timeline", "description": "A timeline of events in the history of Amphetamines", "language": "No language found.", "url": "https://www.erowid.org/chemicals/amphetamines/amphetamines_timeline.php", "drug": "Amphetamine", "cid": 3007, "substance": "amphetamines", "category": "CHEMICALS", "erowid_column": "History", "char_count": 11666, "word_count": 1679, "doc_id": "doc_123", "num_chunks": 16, "chunk_id": "123::chunk_12", "document_index": 123, "latency_s": 0.81305360000988, "prompt_toks": 3279, "completion_toks": 69, "relevance_score": 0.00015000567}, "content": "Drug: Amphetamine | cid: 3007\nSource: erowid | Source description: A timeline of events in the history of Amphetamines\nErowid name: amphetamines\nCategory: CHEMICALS\nField: History\n\n                    Text: \n                    assault and dereliction of duty, Schmidt and Umbach's attorneys claimed it was the Air Force's dextro-amphetamine (trade name, Dexedrine) tablets, aka speed, that killed the Canadians, not Schmidt and Umbach.\" Early 2000s In the United States, states began to restrict sales of ephedrine and pseudoephedrine at the urging of the DEA to try to reduce local methamphetamine production. [Details] Restrictions included setting a maximum amount of ephedrine-containing products (such as two boxes maximum per person), requiring photo ID, and requiring buyers be 18 years old. Jan 1, 2006 In the United States, DEA restrictions added to require sellers of ephedrine or pseudoephedrine-containing products to collect signatures of every purchaser and check identification. [Details] The \"Combat Methamphetamine Epidemic Act of 2005\" provides for criminal penalties for non-compliance with the DEA rules and limits maximum amount any individual can purchase per month to 9 grams. Jul 2, 2007\n\n\n                    Context: \n                    This excerpt covers historical and legal aspects of amphetamine use, specifically highlighting military claims about dextro-amphetamine (\"Dexedrine\") during WWII and subsequent U.S. regulatory measures to control precursor chemicals like ephedrine and pseudoephedrine to curb methamphetamine production, including restrictions implemented from the early 2000s onward.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_17", "document_index": 84, "latency_s": 0.5436048999981722, "prompt_toks": 6387, "completion_toks": 45, "relevance_score": 9.387641e-05}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    References\n\n↑ Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., Guimarães, F. S. (5 December 2012). \"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders\". Philosophical Transactions of the Royal Society B: Biological Sciences. 367 (1607): 3364–3378. doi:10.1098/rstb.2011.0389. ISSN 0962-8436.\n\n↑ \"Epidiolex (Cannabidiol) FDA Label\" (PDF). fda.gov. Retrieved 28 June 2018. For label updates see FDA index page for NDA 210365\n\n↑ 3.0 3.1 FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy, 2018, retrieved 25 June 2018\n\n↑ LaVito, A., DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market\n\n↑ Angell, T. (2018), UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law\n\n\n                    Context: \n                    This references section lists key scientific studies and official sources related to cannabidiol's mechanisms, medical approvals, and legal status, providing foundational evidence supporting the informational content of the full document on cannabidiol (CBD).\n                "}
